When the shutdown ends, said Scott Lassman, JD, partner at Goodwin, “It’s not going to be like flipping a switch…this is going to have longer-term consequences.”
As the US government enters the 25th consecutive day of a partial shutdown that President Trump has warned could stretch for “months or even years,” the FDA is facing dwindling funds that are impacting its capacity to review drug applications.
During the shutdown, the FDA cannot accept any new user fees, and as such, sponsors of new applications will need to wait for the shutdown to end before they can submit their products for review. However, in a January 5 comment on Twitter, FDA Commissioner Scott Gottlieb, MD, indicated that the agency continues to work on existing drug applications for which user fees were paid prior to December 22, 2018, and that the agency had enough funds in its carryover balances from 2018 to fund “about one month” of work. On January 12, Gottlieb tweeted an update that the agency is evaluating when it will “cross a threshold, beyond which, we have to declare that we will not be able to meet medical product user fee goals for 2019.”
Speaking to The Center for Biosimilars® in an interview, Scott Lassman, JD, and Robert Cerwinski, JD, both partners at Goodwin, explained the impact that biosimilar developers will feel from the ongoing shutdown once the FDA runs out of funds.
Lassman, who practices in Goodwin's Technology and Life Sciences Group, says that, while the FDA will attempt to get as much work accomplished as possible before the coffers run dry, programs that are not approved prior to funding running out will be delayed. When the shutdown ends, he added, “It’s not going to be like flipping a switch…this is going to have longer-term consequences.”
Lassman said that developers should expect to encounter long delays as the FDA gets back to work, and he predicted that those delays could last for several months. “I think it’s going to be a mess,” he added.
Industry is likely to remember those delays when negotiating the next Biosimilar User Fee Act (BsUFA) agreement, he added, noting that while the FDA is not required to meet 100% of its goals under the BsUFA, it is likely to receive a spate of negative publicity and criticism from both Congress and industry over missed milestones. However, in this case, the FDA has “a very good explanation” for any goals it fails to reach as a result of the shutdown, said Lassman.
Cerwinski, who focuses on litigation involving pharmaceuticals and biologics, says that the impacts of the shutdown could be keenly felt by smaller biosimilar developers. “The companies that are out there right now burning cash without a product on the market are obviously very sensitive about their launch timeline. A lot of their business planning has been focused around the launch timeline, and if those timelines get pushed for any reason, that’s obviously a significant event for them.”
Bigger companies with more diversified product portfolios will likely feel less of an impact, he said, but even so, biosimilars stem from significant investment, and the date of market entry is a critical factor for developers of all sizes, especially if they are engaged in a race against competitors to be first to market.
Beyond the impact on launch dates, there also exists a potential for the shutdown to impact ongoing patent litigation over biologics. At the moment, said Cerwinski, the US court has enough funding to function as usual through January 18. After that date, limited emergency funding may be made available to provide “essential services.” What services those may be remains unclear, however. The district courts may adopt a district-by-district approach to how they will operate, and the workers who staff those courts may be working without pay for an extended period of time.
With respect to inter partes review (IPR) proceedings before the Patent Trial and Appeal Board of the Patent and Trademark Office (PTO), Cerwinski said, “It may be a little bit of a different story.” Because the PTO, like the FDA, operates under user fees, the office is currently using money collected last year, and has enough funds to operate for approximately 1 month. “We could see a disruption in operation if we go on much longer than a month,” he said, adding that an interruption would likely mean a delay in IPR adjudications.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.